Genicular Nerve Block in Rheuamtoid Arthritis

• Status: Completed
• Trial end date: 2020-07-28
• Target enrollment: 0
• Participant gender: All

Summary

N=64 RA patients either early or established disease diagnosed after ACR/EULAR criteria 2010 with unilateral persistent knee arthritis. They were randomly assigned into two groups; group 1 received genicular nerve block, group 2 intra-articular triamcinolone. Both groups were examined by SOLAR scoring system, Visual analogue scale (VAS) and Lysholm score at 0, 2 and 12 weeks. A semi-quantitative score was used to assess tenderness and swelling at the same intervals.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sohag University
• Treatments: Bupivacaine; Triamcinolone

Criteria

Inclusion Criteria:

• RA patients

• Age > 18

• unilateral persistent knee arthritis

Exclusion Criteria:

• Participants with severe knee osteoarthritis

• peripheral neuropathy

• psoriatic arthritis

• skin infection

• or those who have allergy for Bupivacaine